IR contact detailsRoman Akbar-HaaseDirector Investor Relations and Business Developmente: ir@moonlaketx.com Upcoming events Nov 6 - Nov 11 2026 ACR Convergence 2026 Nov 6 - Nov 8 2026 SHSA 2026 Nov 9 - Nov 10 2026 8th Annual Wolfe Research Healthcare Conference View All Events View All Events + Corporate presentations MoonLake Investor Day (Jun 2026) MoonLake Investor Day (Feb 2026) Clinical Data Update (Nov 2025) View All Presentations View All Presentations + Latest press releases/major announcements Sep 30 2026 MoonLake announces completed submission of HS BLA to U.S. FDA for its nanobody Sonelokimab Aug 10 2026 MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results Jun 23 2026 MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering View All News View All Press Releases +
Sep 30 2026 MoonLake announces completed submission of HS BLA to U.S. FDA for its nanobody Sonelokimab
Aug 10 2026 MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results